Biotek-snakken — September 2017
-
-
-
-
-
Så alt i alt lettere ærgeligt, men så er det heller ikke være - vi står nok til et større fald hvis cabozantinib fejler i anden linie HCC (Celestial studiet), hvilket der er stor risiko for (svær indikation - og første interimanalyse er overstået).
-
-
I pressemeddelelsen fra BMY i går står der at det fulde data sæt fra Opdivo/Yervoy studiet Checkmate-214 præsenteres på ESMO i weekenden https://news.bms.com/press-release/corporatefinancial-news/checkmate-214-study-evaluating-opdivo-combination-yervoy-stopp - det er nok samme præsentation du har linket til Sukker
-
Også interessant at Exelixis Cabosun studiet viste signifikans mht forbedring af PFS http://www.esmo.org/Conferences/Past-Conferences/ESMO-2016-Congress/Press-Media/Cabozantinib-Improves-Progression-free-Survival-in-Metastatic-Renal-Cell-Carcinoma hvilket fejlede for Opdivo/Yervoy. Der er dog stor forskel i PFS mellem de to studier, så man skal som altid passe på med at sammenligne på tværs
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind